Autolus Therapeutics (AUTL) Operating Expenses (2017 - 2025)

Autolus Therapeutics (AUTL) has reported Operating Expenses for 9 consecutive years, with $96.8 million the latest figure, recorded in Q4 2025.

• Quarterly Operating Expenses rose 27.49% year-over-year to $96.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $345.9 million (up 37.52% YoY) and the FY2025 annual result came in at $345.9 million, up 37.52% from the prior year.
• Operating Expenses climbed to $96.8 million in Q4 2025 per AUTL's latest filing, from $92.8 million in the prior quarter.
• Over the last five years, Operating Expenses for AUTL reached as high as $96.8 million in Q4 2025 and fell as low as $15.0 million in Q4 2022.
• A 5-year average of $52.4 million and a median of $43.6 million in 2023 frame the typical range for Operating Expenses.
• Annual changes were most pronounced in 2021 — Operating Expenses plunged 51.24% — and 2023, when it surged 256.09%.
• Year by year, Operating Expenses stood at $23.3 million in 2021, then plunged by 35.73% to $15.0 million in 2022, then jumped by 256.09% to $53.3 million in 2023, then jumped by 42.47% to $75.9 million in 2024, then gained by 27.49% to $96.8 million in 2025.
• According to Business Quant data, Operating Expenses over the past three periods registered $96.8 million, $92.8 million, and $82.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.